Nowadays, the simultaneous inhibition of two or more pathways plays an increasingly important role in cancer treatment due to the complex and diverse pathogenesis of cancer, and the combination of the

NIAID Data Ecosystem50

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

FLT3突变抑制剂

急性髓系白血病药物研究

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesize

NIAID Data Ecosystem20

Toosendanin Suppresses Acute Myeloid Leukemia by Targeting DDX5/c-Myc Axis to inhibit Protein Synthesis

急性髓系白血病药物研究

c-Myc信号通路

The treatment of acute myeloid leukemia (AML) continues to be challenged by relapse and resistance, necessitating the development of novel therapeutic strategies. Toosendanin (TSN), a natural product

NIAID Data Ecosystem70

RNA-seq of MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872. RNA-seq of MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872

LSD1抑制剂转录组

急性髓系白血病药物研究

INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. LSD1 inhibition can induce differentiation of

NIAID Data Ecosystem30

Gene expression and methylation profiling in primary AML cells treated with decitabine and cytarabine

资源简介：

相关数据集